论文部分内容阅读
康健纳胶囊是用于治疗和预防糖尿病的新保健中药。经过四所医院(省、市各两所)历时5年对228例患者的验证(按照WHO标准),总有效率为89.03%,显效率为59.03%。药效学试验结论1.(2g/kg)对正常大鼠的血糖值无影响。2.(2g/kg)能非常显著地抑制alloxan所引起的血糖升高,其作用与D_(360)相当(均为P<0.01)。换而言之,康健纳具有降低动物病理性高血糖的作用。上述临床应用与药效学试验相一致。新药临床首先要考虑的是安全问题,主要是剂量问题。
Kangna capsule is used for the treatment and prevention of diabetes new health medicine. After four hospitals (two provinces and cities) lasted 5 years to 228 patients (according to WHO standards), the total effective rate was 89.03%, the effective rate was 59.03%. Pharmacodynamic Test Conclusion 1. (2g / kg) had no effect on the blood glucose level in normal rats. 2. (2g / kg) can significantly inhibit alloxan caused by elevated blood glucose, its role and D_ (360) were comparable (both P <0.01). In other words, Conner has the effect of reducing pathological hyperglycemia in animals. The above clinical application and pharmacodynamic test are consistent. New drug clinical first thing to consider is the safety issue, mainly the dose problem.